Forbion, through its Forbion Growth Opportunities Fund II, co-led the $70 million round with Sofinnova Partners, alongside significant commitments from existing investors. Nanna Lüneborg, General ...

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization. The Cowen Healthcare Investments-led round comes four years ...

MANCHESTER, United Kingdom, Sept. 12, 2024 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening ...

MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal infections ...

CC0 Usage Conditions ApplyClick for more information. Material is subject to Smithsonian Terms of Use. Should you wish to use NASM material in any medium, please ...

Negative 2174-0077: Goodyear F2G-1 Corsair racer (r/n N5588N) with motor running ...

F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds. Manchester, UK, Sept 5th 2012 - F2G Limited, an antifungal drug discovery ...

Data reinforce olorofim's potential as a first-in-class treatment for patients with invasive fungal diseases and limited or no antifungal treatment options MANCHESTER, United Kingdom, June 18, 2025 ...

MANCHESTER, UK, 4 August 2022 – F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a ...